We are also working with the research sector and industry regarding the preclinical evaluation of therapeutics, to see if they are effective against COVID-19.

The SARS-CoV-2 Screening Program will evaluate potential antiviral compounds for safety and efficacy. This is being undertaken as a collaboration between our Australian Centre for Disease Preparedness (ACDP, formerly known as AAHL) and The Peter Doherty Institute for Infection and Immunology (Doherty Institute).

We are working on the preclinical evaluation of therapeutics, to see if they are effective against COVID-19.

The first stage of the screening program is underway to assesses candidate compounds into three priority groupings, with the most promising compounds selected for a second stage of laboratory testing (in vitro and ex vivo).

The most promising candidates will then be evaluated by our Dangerous Pathogens Team for in vivo efficacy.

Contact us

 
Your contact details
0 / 100
0 / 1900
You shouldn't be able to see this field. Please try again and leave the field blank.

For security reasons attachments are not accepted.